Charles Schwab Investment Management Inc Catalyst Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$527 Billion
Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,246,925 shares of CPRX stock, worth $28.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,246,925

Previous 1,167,743 6.78%

Holding current value

$28.2 Million

Previous $23.2 Million 12.1%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$19.73 - $23.93 $1.56 Million - $1.89 Million	79,182 Added 6.78%	1,246,925 $26 Million
Q3 2024 Nov 12, 2024	BUY	$15.19 - $21.35 $771,712 - $1.08 Million	50,804 Added 4.55%	1,167,743 $23.2 Million
Q2 2024 Aug 12, 2024	BUY	$14.68 - $16.92 $607,458 - $700,149	41,380 Added 3.85%	1,116,939 $17.3 Million
Q1 2024 May 08, 2024	BUY	$13.18 - $17.11 $1.57 Million - $2.04 Million	119,226 Added 12.47%	1,075,559 $17.1 Million
Q4 2023 Feb 06, 2024	BUY	$11.78 - $17.29 $412,370 - $605,253	35,006 Added 3.8%	956,333 $16.1 Million
Q3 2023 Nov 08, 2023	BUY	$11.69 - $15.02 $678,230 - $871,430	58,018 Added 6.72%	921,327 $10.8 Million
Q2 2023 Aug 09, 2023	SELL	$11.5 - $18.08 $4.09 Million - $6.43 Million	-355,866 Reduced 29.19%	863,309 $11.6 Million
Q1 2023 May 11, 2023	SELL	$14.34 - $21.05 $404,947 - $594,430	-28,239 Reduced 2.26%	1,219,175 $20.2 Million
Q4 2022 Feb 13, 2023	BUY	$12.25 - $19.5 $385,911 - $614,308	31,503 Added 2.59%	1,247,414 $23.2 Million
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $243,598 - $535,502	34,504 Added 2.92%	1,215,911 $15.6 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $8.57 $2.18 Million - $3 Million	350,042 Added 42.1%	1,181,407 $8.28 Million
Q1 2022 May 13, 2022	BUY	$5.31 - $8.31 $61,431 - $96,138	11,569 Added 1.41%	831,365 $6.89 Million
Q4 2021 Feb 11, 2022	BUY	$5.21 - $7.45 $96,655 - $138,212	18,552 Added 2.32%	819,796 $5.55 Million
Q3 2021 Nov 16, 2021	BUY	$4.85 - $6.04 $9,724 - $12,110	2,005 Added 0.25%	801,244 $4.25 Million
Q2 2021 Aug 16, 2021	SELL	$4.29 - $6.05 $731,307 - $1.03 Million	-170,468 Reduced 17.58%	799,239 $4.6 Million
Q1 2021 May 17, 2021	SELL	$3.45 - $4.69 $86,363 - $117,404	-25,033 Reduced 2.52%	969,707 $4.47 Million
Q4 2020 Feb 16, 2021	BUY	$2.97 - $3.83 $280,492 - $361,712	94,442 Added 10.49%	994,740 $3.32 Million
Q3 2020 Nov 13, 2020	SELL	$2.97 - $5.08 $15,726 - $26,898	-5,295 Reduced 0.58%	900,298 $2.67 Million
Q2 2020 Aug 14, 2020	BUY	$3.48 - $5.05 $141,754 - $205,706	40,734 Added 4.71%	905,593 $4.18 Million
Q1 2020 May 15, 2020	BUY	$2.61 - $5.21 $143,651 - $286,753	55,039 Added 6.8%	864,859 $3.33 Million
Q4 2019 Feb 07, 2020	BUY	$3.67 - $5.7 $876,550 - $1.36 Million	238,842 Added 41.83%	809,820 $3.04 Million
Q3 2019 Nov 08, 2019	BUY	$3.89 - $7.43 $1.34 Million - $2.56 Million	344,790 Added 152.44%	570,978 $3.03 Million
Q1 2019 May 14, 2019	BUY	$2.11 - $5.33 $37,524 - $94,788	17,784 Added 8.53%	226,188 $1.15 Million
Q2 2018 Aug 08, 2018	BUY	$2.26 - $3.84 $53,109 - $90,240	23,500 Added 12.71%	208,404 $651,000
Q1 2018 May 07, 2018	BUY	$2.39 - $4.01 $86,518 - $145,162	36,200 Added 24.34%	184,904 $442,000
Q4 2017 Jan 17, 2018	BUY	$2.51 - $4.4 $70,792 - $124,097	28,204 Added 23.41%	148,704 $582,000
Q3 2017 Nov 13, 2017	BUY	$2.4 - $2.94 $289,200 - $354,270	120,500	120,500 $304,000

Others Institutions Holding CPRX

# of Institutions

348

Shares Held

98.5M

Call Options Held

13.4K

Put Options Held

11.7K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.32B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Catalyst Pharmaceuticals, Inc. Transaction History